Skip to main content
. 2014 Oct 30;38(3):178–185. doi: 10.1038/hr.2014.156

Table 1. Baseline characteristics of the effectiveness analysis population (n=21 341).

  Age at baseline (years)a
P for trendb
      ⩾75
 
  <65 (n=9817) 65–74 (n=6792) (n=4732) Subgroup ⩾80 (n=2095)  
Age (years) 54.4±7.8 69.5±2.9 79.8±4.1 83.5±3.4 <0.0001
Women 4333 (44.1) 3595 (52.9) 2856 (60.4) 1352 (64.5) <0.0001
Body mass index (kg m−2) 24.99±3.93 24.02±3.33 23.22±3.37 22.77±3.40 <0.0001
Duration of hypertension (years)c 3.92±4.11 5.44±4.49 6.72±4.32 7.03±4.22 <0.0001
           
History
 Cerebrovascular disease 384 (3.9) 509 (7.5) 523 (11.1) 250 (11.9) <0.0001
 Cardiovascular disease 209 (2.1) 354 (5.2) 403 (8.5) 198 (9.5) <0.0001
           
Complications
 Dyslipidemia 4195 (42.7) 3228 (47.5) 2061 (43.6) 824 (39.3) 0.0284
 Diabetes mellitus 1761 (17.9) 1635 (24.1) 968 (20.5) 365 (17.4) <0.0001
 Chronic kidney disease 1117 (11.4) 1476 (21.7) 1691 (35.7) 885 (42.2) <0.0001
Regular alcohol drinkers 2113 (21.5) 956 (14.1) 370 (7.8) 131 (6.3) <0.0001
Current smokers 1808 (18.4) 601 (8.8) 209 (4.4) 59 (2.8) <0.0001
Patients who had received antihypertensive treatment 4141 (42.2) 3701 (54.5) 2890 (61.1) 1315 (62.8) <0.0001
 Calcium channel blockers 2910 (29.6) 2647 (39.0) 2133 (45.1) 972 (46.4) <0.0001
 Angiotensin II receptor blockers 1697 (17.3) 1604 (23.6) 1234 (26.1) 534 (25.5) <0.0001
 β-Blockers 492 (5.0) 474 (7.0) 370 (7.8) 175 (8.4) <0.0001
 Diuretics 408 (4.2) 420 (6.2) 402 (8.5) 203 (9.7) <0.0001
 Angiotensin-converting enzyme inhibitors 274 (2.8) 288 (4.2) 218 (4.6) 103 (4.9) <0.0001
 α-Blockers 143 (1.5) 152 (2.2) 159 (3.4) 65 (3.1) <0.0001
 No. of previous antihypertensive drugs 0.6±0.8 0.8±0.9 1.0±1.0 1.0±1.0 <0.0001
a

Mean±s.d. or n (%).

b

Data were compared between patients aged <65, 65–74 and ⩾75 years. The Cochran–Armitage test was used for categorical variables and the Jonckheere–Terpstra test for continuous variables.

c

Recorded as 10 years for patients who had hypertension for ⩾10 years.